Orchard Therapeutics PLC (ORTX)
| Market Cap | 636.53M |
| Revenue (ttm) | 2.60M |
| Net Income (ttm) | -151.98M |
| Shares Out | 120.55M |
| EPS (ttm) | -1.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $5.06 |
| Previous Close | $5.50 |
| Change ($) | -0.44 |
| Change (%) | -8.00% |
| Day's Open | 5.50 |
| Day's Range | 4.98 - 5.75 |
| Day's Volume | 378,980 |
| 52-Week Range | 3.76 - 10.73 |
Three years after receiving gene therapy from Orchard Therapeutics (NASDAQ: ORTX) in an early-stage clinical trial, 100% of patients with an inherited disease that damages the immune system were still a...
100% overall survival and ≥ 95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
MINNEAPOLIS--(BUSINESS WIRE)--Be The Match BioTherapies announced an expansion of their multi-year partnership with Orchard Therapeutics.
Shares of Orchard Therapeutics (NASDAQ:ORTX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 26.09% year over year to ($0.34), which beat the esti...
$150M Strategic Financing Supports Execution into the First Half of 2023
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following ...
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
The company released some promising data from a pair of proof-of-concept studies.
Orchard Therapeutics Plc (NASDAQ: ORTX) gains in premarket in reaction to positive interim data from a proof-of-concept study evaluating its gene therapy OTL-203 in Mucopolysaccharidosis type I (MPS-I)....
All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment
Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical com...
Strengthened Financial Position Supports Execution into the First Half of 2023 Strengthened Financial Position Supports Execution into the First Half of 2023
Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021 Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021
Nine abstracts accepted demonstrating potential of HSC gene therapy to treat multiple neurodegenerative disorders
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company's commercial reach in the Middle East ...
The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.
Orchard Therapeutics (ORTX) stock is on the rise Wednesday with heavy trading even with there being no major news about the company. The post ORTX Stock Alert: 8 Things to Know About Gene Therapy Play O...
BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Annual J.P. M...
First gene therapy to receive full EU marketing authorization for eligible MLD patients
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Preliminary results from first patient treated with OTL-201 show over expression of the therapeutic enzyme and decrease in substrate levels three months following gene therapy Preliminary results from f...
BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will p...
BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared the c...
These companies are devoted to helping patients who don't have any other options.
BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene Edit...
Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment Preliminary results from first patient in on...
Orchard just received a positive node from CHMP for its lead drug candidate. US approval should be next.
BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New Horizons in...
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company's chief executive officer, Bobby Gaspar, M.D., Ph...
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants
BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority M...
BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the following virtu...
Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression
No news is good news for this biotech company.
BOSTON and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced presentations at the upcoming 46th Annual Meeting of the Europea...
Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript
BOSTON and LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbush PacGrow ...
Orchard Therapeutics: An Undervalued Gene Therapy Company
BOSTON and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has received both orphan drug designation and r...
BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalty-bearing ...
BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s principal cont...
BOSTON and LONDON, May 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made at the fol...
First Primary Outcome Measure Met with All Eight Patients Achieving Hematologic Engraftment
Orchard Therapeutics: A Leading Gene Therapy Company For Your Watchlist
Orchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q1 2020 Results - Earnings Call Transcript
Shares of Orchard Therapeutics (NASDAQ:ORTX) fell 1.5% after the company reported Q1 results.
Orchard Therapeutics: Updating The Investment Thesis
About ORTX
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica... [Read more...]
| Industry Biotechnology | IPO Date Oct 31, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol ORTX |
Financial Performance
In 2020, ORTX's revenue was $2.60 million, an increase of 3.26% compared to the previous year's $2.51 million. Losses were -$151.98 million, -7.00% less than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for ORTX stock is "Strong Buy." The 12-month stock price forecast is 15.11, which is an increase of 198.62% from the latest price.